Dicerna to Report Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
August 03 2017 - 7:30AM
Business Wire
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading
developer of investigational ribonucleic acid interference (RNAi)
therapeutics, today announced that the Company will release its
second quarter 2017 financial results after market close on
Thursday, August 10, 2017.
Management will host a conference call at 4:30 p.m. ET that day
to discuss the Company's financial results and provide a general
business update. The conference call will be webcast live via the
Internet and will be available on the “Investors & Media”
section of the Dicerna website, www.dicerna.com. The webcast will
also be archived on the Company's website.
The call can also be accessed by dialing (855) 453-3834 or (484)
756-4306 (international), and referencing conference ID 38183667
prior to the start of the call. After the conference call, a replay
will be available until August 17, 2017. To access the replay,
please dial (855) 859-2056 or (404) 537-3406, and refer to
conference ID 38183667.
About Dicerna Pharmaceuticals, Inc.
Dicerna Pharmaceuticals, Inc., is a biopharmaceutical company
focused on the discovery and development of innovative RNAi-based
therapeutics for diseases involving the liver, including rare
diseases, chronic liver diseases, cardiovascular diseases, and
viral infectious diseases. The Company is leveraging its
proprietary GalXC™ RNAi technology platform to build a broad
pipeline in these core therapeutic areas, focusing on target genes
where connections between target gene and diseases are well
understood and documented. The Company intends to discover, develop
and commercialize novel therapeutics either on its own or in
collaboration with pharmaceutical partners. For more information,
please visit www.dicerna.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170803005134/en/
Investors:Rx Communications GroupPaula Schwartz,
917-322-2216pschwartz@rxir.comorMedia:SmithSolveAlex Van
Rees, 973-442-1555 ext. 111alex.vanrees@smithsolve.com
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Dicerna Pharmaceuticals (NASDAQ:DRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024